Skip to main content

View full-text article in PMC

. 2022 Jul 16;104(2):115770. doi: 10.1016/j.diagmicrobio.2022.115770

Table 4.

Assay sensitivity and specificity by device type.

		Neoteryx mitra (N = 126)^a		Tasso-SST (N = 113)^a
		Antibody positive	Antibody negative	Antibody positive	Antibody negative
InBios Spike IgG (4 uL)^c	COVID-19 Dx and/or vaccinated^d	35	23	63	2
	No COVID-19 Dx/not vaccinated	8	60	5	20
	Sensitivity	0.60		0.97
	Specificity	0.88		0.80
BioRad (Total NC^b Ab) (15 uL)	COVID-19 Dx and/or vaccinated	19	39	30	37
	No COVID-19 Dx/not vaccinated	4	64	3	42
	Sensitivity	0.33		0.45
	Specificity	0.94		0.93
Abbott NC^b IgG (125 uL)	COVID-19 Dx and/or vaccinated	11	47	14	27
	No COVID-19 Dx/not vaccinated	2	66	3	29
	Sensitivity	0.19		0.34
	Specificity	0.97		0.91
Abbott Spike IgG II (125 uL)	COVID-19 Dx and/or vaccinated	46	7	47	1
	No COVID-19 Dx/not vaccinated	9	4	5	0
	Sensitivity	0.87		0.98
	Specificity	0.31		0.00

^a

Due to volume restrictions, not all samples were tested for all assays.

^b

NC = nucleocapsid.

^c

Sample volume required for assay.

^d

Defined as a positive COVID test from EHR or self-reported COVID diagnosis from survey, or having received at least 1 dose before pilot consent date.

Some subjects may have had COVID-19 infection and were not tested.